Our present study demonstrates that GSK343, an inhibitor of EZH2, suppresses the proliferation, invasion, and cancer stem-like phenotypes and reverses mesenchymal transition of glioma cells in vitro and in vivo. This evidence concerns the gene EZH2 and central nervous system cancer.